2017
Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Philipp S, Spelman L, Zhang N, Strober B. Clinical similarity of the biosimilar ABP 501 compared with adalimumab after single transition: long‐term results from a randomized controlled, double‐blind, 52‐week, phase III trial in patients with moderate‐to‐severe plaque psoriasis. British Journal Of Dermatology 2017, 177: 1562-1574. PMID: 28755394, DOI: 10.1111/bjd.15857.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisBody surface areaABP 501Week 16Adverse eventsAntidrug antibodiesPlaque psoriasisBiosimilar ABP 501New safety signalsPercentage of patientsPhase III trialsSimilar clinical efficacySeverity Index scorePercentage body surface areaLong-term resultsEuropean Medicines AgencyPASI 50PASI improvementWeek 52III trialsPsoriasis AreaAdalimumab patientsImmunogenicity profileClinical efficacyPatient population
2013
Pharmacovigilance and biosimilars: considerations, needs and challenges
Casadevall N, Edwards I, Felix T, Graze P, Litten J, Strober B, Warnock D. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opinion On Biological Therapy 2013, 13: 1039-1047. PMID: 23527621, DOI: 10.1517/14712598.2013.783560.Peer-Reviewed Original Research
2012
Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know
Strober B, Armour K, Romiti R, Smith C, Tebbey P, Menter A, Leonardi C. Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. Journal Of The American Academy Of Dermatology 2012, 66: 317-322. PMID: 22243723, DOI: 10.1016/j.jaad.2011.08.034.Peer-Reviewed Original ResearchConceptsTreatment of psoriasisOptimal therapy managementImmune-mediated disordersBiosimilar formPsoriasis populationAppropriate therapyTopical agentsTherapy managementBiosimilar agentsClinical relevanceGeneric therapiesPatient careTherapyPsoriasisImportant interventionDevelopment of biosimilarsPatientsBiosimilarsDermatologistsTreatmentBiopharmaceutical therapiesAgentsImportant differencesPrescribersRegulatory guidelines
2007
The use of therapeutic interchange for biologic therapies.
Flood J, Mihalik C, Fleming R, Strober B, Zucker D, Burgoyne D. The use of therapeutic interchange for biologic therapies. Managed Care 2007, 16: 51-62. PMID: 17285813.Peer-Reviewed Original ResearchMeSH KeywordsBiological TherapyChronic DiseaseDisease ManagementHumansPharmaceutical ServicesTherapeutic EquivalencyUnited StatesConceptsSelective serotonin reuptake inhibitorsProton pump inhibitorsBiologic agentsTherapeutic interchangeRheumatoid arthritisBiologic therapyHMG-CoA reductase inhibitorsSerotonin reuptake inhibitorsPopulation-based outcomesHealth care professionalsMode of administrationOverall treatment costsTolerability profileAppropriate therapyReuptake inhibitorsPsoriasis therapyPump inhibitorsDrug classesIndividual patientsCare professionalsNew agentsEnzyme inhibitorsPatientsReductase inhibitorsTherapy